Lymeclin408 mg

Lymeclin is a tetracycline-class antibiotic used for the following indications:

Established / Approved Uses

• Moderate to severe acne vulgaris, particularly inflammatory acne, as part of a comprehensive skin-care regimen.
• Treatment of susceptible bacterial infections, including:
  • Respiratory tract infections (e.g., bronchitis, sinusitis)
  • Urinary tract infections caused by susceptible organisms
  • Skin and soft tissue infections
  • Infections caused by atypical organisms such as Chlamydia, Mycoplasma, and Rickettsia species

Adjunct / Off-label Uses

• Rosacea (used off-label in some regions for its anti-inflammatory and antibacterial effects).

Lymeclin should only be used for infections confirmed or strongly suspected to be caused by susceptible bacteria; it is not effective against viral infections.

Each capsule of Lymecycline contains Lymecycline (INN) 408 mg, equivalent to approximately 300 mg of tetracycline base.

Lymeclin is a semisynthetic, highly water-soluble tetracycline-class antibiotic (a lysine conjugate of tetracycline). Its high solubility allows it to be absorbed via an active carrier-mediated transport mechanism in the intestine, similar to that used for amino acids, giving it more predictable absorption than some older tetracyclines. Lymeclin is used both as an antibacterial agent and, at standard doses, in the long-term management of inflammatory acne.

Tetracycline-class antibiotic (Tetracyclines), ATC code J01AA04.

Lymecycline is a bacteriostatic antibiotic. It works by reversibly binding to the 30S ribosomal subunit of susceptible bacteria, blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex and thereby inhibiting bacterial protein synthesis.

Lymecycline has activity against a broad range of gram-positive and gram-negative bacteria, as well as atypical organisms such as Chlamydia, Mycoplasma, and Rickettsia species. In acne, Lymecycline also reduces inflammation by inhibiting bacterial lipases produced by Cutibacterium acnes and by direct anti-inflammatory effects, independent of its antibacterial action.

Pharmacokinetics

• Absorption: Rapidly and almost completely absorbed from the gastrointestinal tract via an active transport mechanism; less affected by food than some other tetracyclines, though co-administration with divalent/trivalent cations still markedly reduces absorption.
• Distribution: Widely distributed into body tissues and fluids; crosses the placenta and is present in breast milk.
• Elimination: Excreted mainly unchanged via the kidneys and, to a lesser extent, in the bile/faeces.

Lymeclin capsules should be swallowed whole with a full glass of water, taken at roughly the same time each day, and not taken immediately before lying down. It can be taken with or without food; separate dosing from antacids, dairy, and mineral supplements by 2-3 hours.

Common

• Nausea, vomiting, diarrhea, abdominal pain
• Headache
• Photosensitivity (increased skin sensitivity to sunlight)

Less Common / Rare

• Rash, dermatitis, hypersensitivity reactions
• Esophageal irritation/esophagitis (see Precautions for prevention)
• Hepatotoxicity (elevated liver enzymes, jaundice - dark urine, yellowing of skin/eyes)
• Pseudotumor cerebri / benign intracranial hypertension (headache, visual disturbances) - rare, more common with concurrent retinoid use
• Visual disturbances
• Superinfection, including oral or vaginal candidiasis, with prolonged use

Seek immediate medical attention for signs of a severe allergic reaction (swelling of face/lips/throat, difficulty breathing, severe rash) or symptoms of liver problems while taking Lymeclin.

Lymeclin is contraindicated during pregnancy, as tetracyclines cross the placenta and can cause permanent discoloration of the child's teeth and inhibit bone growth if used during the second and third trimesters. Lymeclin should not be used during pregnancy; if pregnancy occurs or is suspected during treatment, a physician should be consulted immediately to switch to an alternative antibiotic.

Lymeclin passes into breast milk and is generally not recommended during breastfeeding. If use during breastfeeding is considered unavoidable by a physician, it should be limited to short courses, with the infant monitored for feeding problems, diarrhea, rash, or oral thrush; consult a physician before use.

• Photosensitivity: Lymeclin may increase sensitivity to sunlight and UV light; avoid excessive sun exposure and use sun protection during treatment.
• Esophageal irritation: take with adequate water and remain upright (avoid lying down) for at least 30 minutes after dosing.
• Pseudotumor cerebri: rare; discontinue and seek medical advice promptly if severe headache or visual disturbances occur, especially if taken with oral retinoids.
• Reduced oral contraceptive efficacy: a debated, theoretical interaction; advise backup contraception during treatment.
• Absorption interference: avoid concurrent antacids, dairy products, or iron/mineral supplements - see Interactions.
• Renal/hepatic impairment: use with caution; see Use in Special Populations.
• Superinfection: prolonged use may result in overgrowth of non-susceptible organisms, including Clostridioides difficile-associated diarrhea.
• Autoimmune conditions: use with caution in patients with systemic lupus erythematosus or myasthenia gravis, as tetracyclines may worsen these conditions.
• Antibiotic stewardship: Take Lymeclin exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice.

Symptoms of Lymeclin overdose may include nausea, vomiting, diarrhea, and abdominal discomfort. There is no specific antidote. In case of a suspected overdose, seek immediate medical attention or contact a poison control center; do not attempt home treatment. Supportive care and monitoring will be provided by medical professionals as needed.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not use beyond the expiry date printed on the pack.

• Pregnancy: Contraindicated - see Pregnancy and Lactation.
• Breastfeeding: Not recommended - see Pregnancy and Lactation.
• Children under 8 years: Contraindicated due to effects on teeth and bone development.
• Children 8-12 years: Not generally recommended; use only if a physician determines benefits outweigh risks.
• Elderly: No specific dose adjustment is generally required, but renal function should be considered.
• Renal impairment: Use with caution; may require dose adjustment or avoidance in severe impairment.
• Hepatic impairment: Use with caution; monitor liver function during prolonged treatment.

For acne vulgaris, Lymeclin is typically used for a minimum of 8 weeks, with reassessment of response by 12 weeks (3 months); if no improvement is seen, an alternative treatment should be considered. For bacterial infections, the duration of Lymeclin treatment is generally 7-14 days depending on the type and severity of infection, as directed by a physician. The full course should always be completed even if symptoms improve early.

Tetracyclines; Antibacterials for systemic use (ATC classification: J01AA04).

Lymecycline inhibits bacterial protein synthesis by reversibly binding to the 30S ribosomal subunit, preventing attachment of aminoacyl-tRNA to the mRNA-ribosome complex. This bacteriostatic action, combined with anti-inflammatory effects on sebaceous gland activity and Cutibacterium acnes-related inflammation, underlies its efficacy in both bacterial infections and acne.

Lymeclin is contraindicated in children under 8 years of age due to the risk of permanent tooth discoloration and inhibition of bone growth. It is generally not recommended for children under 12 years of age. In adolescents 12 years and older, Lymeclin may be used at the standard adult dose for approved indications such as acne vulgaris and susceptible infections, under medical supervision. Safety and efficacy in children under 8 years have not been established and use is contraindicated in this age group.